Global Lymphoedema Diagnostics Market
Global Lymphoedema Diagnostics Market

Lymphoedema Diagnostics Comprehensive Study by Type (Surgery, Compression, Others), Application (Hospitals, Diagnostic Centres, Research and Academic Centres, Others), Disease Type (Cardiovascular Diseases, Cancer, Inflammatory Diseases, Others), Technology (Lymphoscintigraphy, X-ray Lymphography, Computed Tomography, Magnetic Resonance Imaging, Fluorescein Sodium Microlymphangiography, Ultrasound Imaging, ICG Lymphography, Bioimpedance Analysis, Near-infrared Fluorescence Imaging) Players and Region - Global Market Outlook to 2026

Lymphoedema Diagnostics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 226 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Lymphoedema Diagnostics Market Scope?
Lymphedema is defined as a long-term condition during which excess fluids accumulate in tissues resulting in swelling. Lymphedema is additionally called humor obstruction that ordinarily affects arms and legs. Some patients even experience swelling within the private parts, head, and chest. Two main styles of lymphedema include primary Lymphedema and secondary Lymphedema. Primary Lymphedema is additionally called noninheritable Lymphedema. Secondary Lymphedema happens due to alternative reasons like cancer, inflammation, infection, injury, and trauma, among others. Though lymphedema is incurable, treatment is obtainable for reducing the swelling. The common mode of treatment used includes advanced decongestive medical aid. This medical aid includes remedial exercises, skin care, manual humor drain, and multilayer Lymphedema dressing. The main explanation for Lymphedema is taken into account to be genetic mutations in genes concerned within the development of the vascular system. Secondary causes of the malady embrace cancer surgery, therapy, infection, and inflammatory conditions, among others. Lymphedema increases the danger of infections and alternative complications, as lymphocytes don't seem to be able to reach components of the body wherever the swelling happens.

The Lymphoedema Diagnostics market study is being classified by Type (Surgery, Compression and Others), by Application (Hospitals, Diagnostic Centres, Research and Academic Centres and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from Asian will contribute to the maximum growth of Global Lymphoedema Diagnostics market throughout the predicted period.

General Electric Company (United States), Siemens AG (Germany), Koninklijke Philips N.V. (Netherlands), Canon, Inc. (Japan), Stryker Corporation (United States), Hitachi, Ltd. (Japan), Neusoft Corporation (China), Esaote SPA (Italy), Shimadzu Corporation (Japan) and Mindray Medical International Limited (China) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Lymphoedema Diagnostics market by Type, Application and Region.

On the basis of geography, the market of Lymphoedema Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In March 2016, ImpediMed announced the launch of their new technology which is specially designed for the fast diagnosis of lymphedema in cancer patients.


Influencing Market Trend
  • Increasing Adoption by the Doctors

Market Drivers
  • The Prevalence of Chronic Lymphedema
  • Prevalence of Primary Lymphedema
  • Increase in the Geriatric Population

Opportunities
  • Increasing Advancement in the Technology Used to Diagnose

Restraints
  • High Cost Associated with the Devices

Challenges
  • Presence of Substitute Diagnosis Methods


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Lymphoedema Diagnostics, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Surgery
  • Compression
  • Others
By Application
  • Hospitals
  • Diagnostic Centres
  • Research and Academic Centres
  • Others
By Disease Type
  • Cardiovascular Diseases
  • Cancer
  • Inflammatory Diseases
  • Others

By Technology
  • Lymphoscintigraphy
  • X-ray Lymphography
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Fluorescein Sodium Microlymphangiography
  • Ultrasound Imaging
  • ICG Lymphography
  • Bioimpedance Analysis
  • Near-infrared Fluorescence Imaging

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Prevalence of Chronic Lymphedema
      • 3.2.2. Prevalence of Primary Lymphedema
      • 3.2.3. Increase in the Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Presence of Substitute Diagnosis Methods
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption by the Doctors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lymphoedema Diagnostics, by Type, Application, Disease Type, Technology and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Lymphoedema Diagnostics (Value)
      • 5.2.1. Global Lymphoedema Diagnostics by: Type (Value)
        • 5.2.1.1. Surgery
        • 5.2.1.2. Compression
        • 5.2.1.3. Others
      • 5.2.2. Global Lymphoedema Diagnostics by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostic Centres
        • 5.2.2.3. Research and Academic Centres
        • 5.2.2.4. Others
      • 5.2.3. Global Lymphoedema Diagnostics by: Disease Type (Value)
        • 5.2.3.1. Cardiovascular Diseases
        • 5.2.3.2. Cancer
        • 5.2.3.3. Inflammatory Diseases
        • 5.2.3.4. Others
      • 5.2.4. Global Lymphoedema Diagnostics by: Technology (Value)
        • 5.2.4.1. Lymphoscintigraphy
        • 5.2.4.2. X-ray Lymphography
        • 5.2.4.3. Computed Tomography
        • 5.2.4.4. Magnetic Resonance Imaging
        • 5.2.4.5. Fluorescein Sodium Microlymphangiography
        • 5.2.4.6. Ultrasound Imaging
        • 5.2.4.7. ICG Lymphography
        • 5.2.4.8. Bioimpedance Analysis
        • 5.2.4.9. Near-infrared Fluorescence Imaging
      • 5.2.5. Global Lymphoedema Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Lymphoedema Diagnostics (Price)
      • 5.3.1. Global Lymphoedema Diagnostics by: Type (Price)
  • 6. Lymphoedema Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. General Electric Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Siemens AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Koninklijke Philips N.V. (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Canon, Inc. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Stryker Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hitachi, Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neusoft Corporation (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Esaote SPA (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shimadzu Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mindray Medical International Limited (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lymphoedema Diagnostics Sale, by Type, Application, Disease Type, Technology and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Lymphoedema Diagnostics (Value)
      • 7.2.1. Global Lymphoedema Diagnostics by: Type (Value)
        • 7.2.1.1. Surgery
        • 7.2.1.2. Compression
        • 7.2.1.3. Others
      • 7.2.2. Global Lymphoedema Diagnostics by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostic Centres
        • 7.2.2.3. Research and Academic Centres
        • 7.2.2.4. Others
      • 7.2.3. Global Lymphoedema Diagnostics by: Disease Type (Value)
        • 7.2.3.1. Cardiovascular Diseases
        • 7.2.3.2. Cancer
        • 7.2.3.3. Inflammatory Diseases
        • 7.2.3.4. Others
      • 7.2.4. Global Lymphoedema Diagnostics by: Technology (Value)
        • 7.2.4.1. Lymphoscintigraphy
        • 7.2.4.2. X-ray Lymphography
        • 7.2.4.3. Computed Tomography
        • 7.2.4.4. Magnetic Resonance Imaging
        • 7.2.4.5. Fluorescein Sodium Microlymphangiography
        • 7.2.4.6. Ultrasound Imaging
        • 7.2.4.7. ICG Lymphography
        • 7.2.4.8. Bioimpedance Analysis
        • 7.2.4.9. Near-infrared Fluorescence Imaging
      • 7.2.5. Global Lymphoedema Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Lymphoedema Diagnostics (Price)
      • 7.3.1. Global Lymphoedema Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lymphoedema Diagnostics: by Type(USD Million)
  • Table 2. Lymphoedema Diagnostics Surgery , by Region USD Million (2015-2020)
  • Table 3. Lymphoedema Diagnostics Compression , by Region USD Million (2015-2020)
  • Table 4. Lymphoedema Diagnostics Others , by Region USD Million (2015-2020)
  • Table 5. Lymphoedema Diagnostics: by Application(USD Million)
  • Table 6. Lymphoedema Diagnostics Hospitals , by Region USD Million (2015-2020)
  • Table 7. Lymphoedema Diagnostics Diagnostic Centres , by Region USD Million (2015-2020)
  • Table 8. Lymphoedema Diagnostics Research and Academic Centres , by Region USD Million (2015-2020)
  • Table 9. Lymphoedema Diagnostics Others , by Region USD Million (2015-2020)
  • Table 10. Lymphoedema Diagnostics: by Disease Type(USD Million)
  • Table 11. Lymphoedema Diagnostics Cardiovascular Diseases , by Region USD Million (2015-2020)
  • Table 12. Lymphoedema Diagnostics Cancer , by Region USD Million (2015-2020)
  • Table 13. Lymphoedema Diagnostics Inflammatory Diseases , by Region USD Million (2015-2020)
  • Table 14. Lymphoedema Diagnostics Others , by Region USD Million (2015-2020)
  • Table 15. Lymphoedema Diagnostics: by Technology(USD Million)
  • Table 16. Lymphoedema Diagnostics Lymphoscintigraphy , by Region USD Million (2015-2020)
  • Table 17. Lymphoedema Diagnostics X-ray Lymphography , by Region USD Million (2015-2020)
  • Table 18. Lymphoedema Diagnostics Computed Tomography , by Region USD Million (2015-2020)
  • Table 19. Lymphoedema Diagnostics Magnetic Resonance Imaging , by Region USD Million (2015-2020)
  • Table 20. Lymphoedema Diagnostics Fluorescein Sodium Microlymphangiography , by Region USD Million (2015-2020)
  • Table 21. Lymphoedema Diagnostics Ultrasound Imaging , by Region USD Million (2015-2020)
  • Table 22. Lymphoedema Diagnostics ICG Lymphography , by Region USD Million (2015-2020)
  • Table 23. Lymphoedema Diagnostics Bioimpedance Analysis , by Region USD Million (2015-2020)
  • Table 24. Lymphoedema Diagnostics Near-infrared Fluorescence Imaging , by Region USD Million (2015-2020)
  • Table 25. South America Lymphoedema Diagnostics, by Country USD Million (2015-2020)
  • Table 26. South America Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 27. South America Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 28. South America Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 29. South America Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 30. Brazil Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 31. Brazil Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 32. Brazil Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 33. Brazil Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 34. Argentina Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 35. Argentina Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 36. Argentina Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 37. Argentina Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 38. Rest of South America Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 39. Rest of South America Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 40. Rest of South America Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 41. Rest of South America Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 42. Asia Pacific Lymphoedema Diagnostics, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 44. Asia Pacific Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 45. Asia Pacific Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 46. Asia Pacific Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 47. China Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 48. China Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 49. China Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 50. China Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 51. Japan Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 52. Japan Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 53. Japan Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 54. Japan Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 55. India Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 56. India Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 57. India Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 58. India Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 59. South Korea Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 60. South Korea Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 61. South Korea Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 62. South Korea Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 63. Taiwan Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 64. Taiwan Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 65. Taiwan Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 66. Taiwan Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 67. Australia Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 68. Australia Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 69. Australia Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 70. Australia Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 75. Europe Lymphoedema Diagnostics, by Country USD Million (2015-2020)
  • Table 76. Europe Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 77. Europe Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 78. Europe Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 79. Europe Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 80. Germany Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 81. Germany Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 82. Germany Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 83. Germany Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 84. France Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 85. France Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 86. France Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 87. France Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 88. Italy Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 89. Italy Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 90. Italy Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 91. Italy Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 92. United Kingdom Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 93. United Kingdom Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 94. United Kingdom Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 95. United Kingdom Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 96. Netherlands Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 97. Netherlands Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 98. Netherlands Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 99. Netherlands Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 100. Rest of Europe Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 101. Rest of Europe Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 102. Rest of Europe Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 103. Rest of Europe Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 104. MEA Lymphoedema Diagnostics, by Country USD Million (2015-2020)
  • Table 105. MEA Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 106. MEA Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 107. MEA Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 108. MEA Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 109. Middle East Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 110. Middle East Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 111. Middle East Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 112. Middle East Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 113. Africa Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 114. Africa Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 115. Africa Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 116. Africa Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 117. North America Lymphoedema Diagnostics, by Country USD Million (2015-2020)
  • Table 118. North America Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 119. North America Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 120. North America Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 121. North America Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 122. United States Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 123. United States Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 124. United States Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 125. United States Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 126. Canada Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 127. Canada Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 128. Canada Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 129. Canada Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 130. Mexico Lymphoedema Diagnostics, by Type USD Million (2015-2020)
  • Table 131. Mexico Lymphoedema Diagnostics, by Application USD Million (2015-2020)
  • Table 132. Mexico Lymphoedema Diagnostics, by Disease Type USD Million (2015-2020)
  • Table 133. Mexico Lymphoedema Diagnostics, by Technology USD Million (2015-2020)
  • Table 134. Lymphoedema Diagnostics: by Type(USD/Units)
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Lymphoedema Diagnostics: by Type(USD Million)
  • Table 146. Lymphoedema Diagnostics Surgery , by Region USD Million (2021-2026)
  • Table 147. Lymphoedema Diagnostics Compression , by Region USD Million (2021-2026)
  • Table 148. Lymphoedema Diagnostics Others , by Region USD Million (2021-2026)
  • Table 149. Lymphoedema Diagnostics: by Application(USD Million)
  • Table 150. Lymphoedema Diagnostics Hospitals , by Region USD Million (2021-2026)
  • Table 151. Lymphoedema Diagnostics Diagnostic Centres , by Region USD Million (2021-2026)
  • Table 152. Lymphoedema Diagnostics Research and Academic Centres , by Region USD Million (2021-2026)
  • Table 153. Lymphoedema Diagnostics Others , by Region USD Million (2021-2026)
  • Table 154. Lymphoedema Diagnostics: by Disease Type(USD Million)
  • Table 155. Lymphoedema Diagnostics Cardiovascular Diseases , by Region USD Million (2021-2026)
  • Table 156. Lymphoedema Diagnostics Cancer , by Region USD Million (2021-2026)
  • Table 157. Lymphoedema Diagnostics Inflammatory Diseases , by Region USD Million (2021-2026)
  • Table 158. Lymphoedema Diagnostics Others , by Region USD Million (2021-2026)
  • Table 159. Lymphoedema Diagnostics: by Technology(USD Million)
  • Table 160. Lymphoedema Diagnostics Lymphoscintigraphy , by Region USD Million (2021-2026)
  • Table 161. Lymphoedema Diagnostics X-ray Lymphography , by Region USD Million (2021-2026)
  • Table 162. Lymphoedema Diagnostics Computed Tomography , by Region USD Million (2021-2026)
  • Table 163. Lymphoedema Diagnostics Magnetic Resonance Imaging , by Region USD Million (2021-2026)
  • Table 164. Lymphoedema Diagnostics Fluorescein Sodium Microlymphangiography , by Region USD Million (2021-2026)
  • Table 165. Lymphoedema Diagnostics Ultrasound Imaging , by Region USD Million (2021-2026)
  • Table 166. Lymphoedema Diagnostics ICG Lymphography , by Region USD Million (2021-2026)
  • Table 167. Lymphoedema Diagnostics Bioimpedance Analysis , by Region USD Million (2021-2026)
  • Table 168. Lymphoedema Diagnostics Near-infrared Fluorescence Imaging , by Region USD Million (2021-2026)
  • Table 169. South America Lymphoedema Diagnostics, by Country USD Million (2021-2026)
  • Table 170. South America Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 171. South America Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 172. South America Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 173. South America Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 174. Brazil Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 175. Brazil Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 176. Brazil Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 177. Brazil Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 178. Argentina Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 179. Argentina Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 180. Argentina Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 181. Argentina Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 182. Rest of South America Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 183. Rest of South America Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 184. Rest of South America Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 185. Rest of South America Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 186. Asia Pacific Lymphoedema Diagnostics, by Country USD Million (2021-2026)
  • Table 187. Asia Pacific Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 188. Asia Pacific Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 189. Asia Pacific Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 190. Asia Pacific Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 191. China Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 192. China Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 193. China Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 194. China Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 195. Japan Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 196. Japan Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 197. Japan Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 198. Japan Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 199. India Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 200. India Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 201. India Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 202. India Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 203. South Korea Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 204. South Korea Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 205. South Korea Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 206. South Korea Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 207. Taiwan Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 208. Taiwan Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 209. Taiwan Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 210. Taiwan Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 211. Australia Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 212. Australia Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 213. Australia Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 214. Australia Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 216. Rest of Asia-Pacific Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 217. Rest of Asia-Pacific Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 218. Rest of Asia-Pacific Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 219. Europe Lymphoedema Diagnostics, by Country USD Million (2021-2026)
  • Table 220. Europe Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 221. Europe Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 222. Europe Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 223. Europe Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 224. Germany Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 225. Germany Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 226. Germany Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 227. Germany Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 228. France Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 229. France Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 230. France Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 231. France Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 232. Italy Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 233. Italy Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 234. Italy Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 235. Italy Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 236. United Kingdom Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 237. United Kingdom Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 238. United Kingdom Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 239. United Kingdom Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 240. Netherlands Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 241. Netherlands Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 242. Netherlands Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 243. Netherlands Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 244. Rest of Europe Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 245. Rest of Europe Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 246. Rest of Europe Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 247. Rest of Europe Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 248. MEA Lymphoedema Diagnostics, by Country USD Million (2021-2026)
  • Table 249. MEA Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 250. MEA Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 251. MEA Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 252. MEA Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 253. Middle East Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 254. Middle East Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 255. Middle East Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 256. Middle East Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 257. Africa Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 258. Africa Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 259. Africa Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 260. Africa Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 261. North America Lymphoedema Diagnostics, by Country USD Million (2021-2026)
  • Table 262. North America Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 263. North America Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 264. North America Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 265. North America Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 266. United States Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 267. United States Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 268. United States Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 269. United States Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 270. Canada Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 271. Canada Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 272. Canada Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 273. Canada Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 274. Mexico Lymphoedema Diagnostics, by Type USD Million (2021-2026)
  • Table 275. Mexico Lymphoedema Diagnostics, by Application USD Million (2021-2026)
  • Table 276. Mexico Lymphoedema Diagnostics, by Disease Type USD Million (2021-2026)
  • Table 277. Mexico Lymphoedema Diagnostics, by Technology USD Million (2021-2026)
  • Table 278. Lymphoedema Diagnostics: by Type(USD/Units)
  • Table 279. Research Programs/Design for This Report
  • Table 280. Key Data Information from Secondary Sources
  • Table 281. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lymphoedema Diagnostics: by Type USD Million (2015-2020)
  • Figure 5. Global Lymphoedema Diagnostics: by Application USD Million (2015-2020)
  • Figure 6. Global Lymphoedema Diagnostics: by Disease Type USD Million (2015-2020)
  • Figure 7. Global Lymphoedema Diagnostics: by Technology USD Million (2015-2020)
  • Figure 8. South America Lymphoedema Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Lymphoedema Diagnostics Share (%), by Country
  • Figure 10. Europe Lymphoedema Diagnostics Share (%), by Country
  • Figure 11. MEA Lymphoedema Diagnostics Share (%), by Country
  • Figure 12. North America Lymphoedema Diagnostics Share (%), by Country
  • Figure 13. Global Lymphoedema Diagnostics: by Type USD/Units (2015-2020)
  • Figure 14. Global Lymphoedema Diagnostics share by Players 2020 (%)
  • Figure 15. Global Lymphoedema Diagnostics share by Players (Top 3) 2020(%)
  • Figure 16. Global Lymphoedema Diagnostics share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. General Electric Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. General Electric Company (United States) Revenue: by Geography 2020
  • Figure 20. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens AG (Germany) Revenue: by Geography 2020
  • Figure 22. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 23. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 24. Canon, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Canon, Inc. (Japan) Revenue: by Geography 2020
  • Figure 26. Stryker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Stryker Corporation (United States) Revenue: by Geography 2020
  • Figure 28. Hitachi, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Hitachi, Ltd. (Japan) Revenue: by Geography 2020
  • Figure 30. Neusoft Corporation (China) Revenue, Net Income and Gross profit
  • Figure 31. Neusoft Corporation (China) Revenue: by Geography 2020
  • Figure 32. Esaote SPA (Italy) Revenue, Net Income and Gross profit
  • Figure 33. Esaote SPA (Italy) Revenue: by Geography 2020
  • Figure 34. Shimadzu Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Shimadzu Corporation (Japan) Revenue: by Geography 2020
  • Figure 36. Mindray Medical International Limited (China) Revenue, Net Income and Gross profit
  • Figure 37. Mindray Medical International Limited (China) Revenue: by Geography 2020
  • Figure 38. Global Lymphoedema Diagnostics: by Type USD Million (2021-2026)
  • Figure 39. Global Lymphoedema Diagnostics: by Application USD Million (2021-2026)
  • Figure 40. Global Lymphoedema Diagnostics: by Disease Type USD Million (2021-2026)
  • Figure 41. Global Lymphoedema Diagnostics: by Technology USD Million (2021-2026)
  • Figure 42. South America Lymphoedema Diagnostics Share (%), by Country
  • Figure 43. Asia Pacific Lymphoedema Diagnostics Share (%), by Country
  • Figure 44. Europe Lymphoedema Diagnostics Share (%), by Country
  • Figure 45. MEA Lymphoedema Diagnostics Share (%), by Country
  • Figure 46. North America Lymphoedema Diagnostics Share (%), by Country
  • Figure 47. Global Lymphoedema Diagnostics: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • General Electric Company (United States)
  • Siemens AG (Germany)
  • Koninklijke Philips N.V. (Netherlands)
  • Canon, Inc. (Japan)
  • Stryker Corporation (United States)
  • Hitachi, Ltd. (Japan)
  • Neusoft Corporation (China)
  • Esaote SPA (Italy)
  • Shimadzu Corporation (Japan)
  • Mindray Medical International Limited (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation